L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin Care Claims
This article was originally published in The Tan Sheet
A proposed consent agreement with FTC bars L’Oreal USA from claiming its Lancome and L’Oreal Paris skin-care products target users’ genes with anti-aging benefits. The settlement, subject to public comment and final FTC approval, follows a 2012 FDA warning that cited some of the same marketing claims.
You may also be interested in...
Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.
Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.
Plaintiffs against Florida-based Green Roads used certificates of analysis the company makes freely available to consumers to determine that batches of two of the company’s products contained “significantly” less cannabidiol versus labeled amounts. A Florida federal court rejected the firm’s motion to dismiss, but it is interested in seeing how FDA rulemaking develops.